{"version":"1.0","provider_name":"hollandbio","provider_url":"https:\/\/www.hollandbio.nl\/en\/","title":"Novo Nordisk acquires Ziylo for 800 million USD - hollandbio","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"VDp1me1bap\"><a href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/novo-nordisk-acquires-ziylo-for-800-million-usd\/\">Novo Nordisk acquires Ziylo for 800 million USD<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/novo-nordisk-acquires-ziylo-for-800-million-usd\/embed\/#?secret=VDp1me1bap\" width=\"600\" height=\"338\" title=\"&#8220;Novo Nordisk acquires Ziylo for 800 million USD&#8221; &#8212; hollandbio\" data-secret=\"VDp1me1bap\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.hollandbio.nl\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. The acquisition gives Novo Nordisk full rights to Ziylo\u2019s glucose binding molecule platform to develop glucose responsive insulins.\u00a0Ziylo\u2019s glucose binding molecules are synthetic molecules that were designed by Professor Anthony [&hellip;]","thumbnail_url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","thumbnail_width":1200,"thumbnail_height":675}